Injective (INJ) is currently trading at $3.83, reflecting a slight decline of 0.16% over the last 24 hours. The price is oscillating within a daily range of $3.80 to $3.94, indicating limited volatility as evidenced by a daily range of just 0.14%.

The trading volume stands at approximately 77.97 million, representing a volume-to-market cap ratio of 20.37%, suggesting healthy trading activity relative to its market capitalization. The short-term moving averages, particularly the 8 SMA at $3.84 and the 13 SMA at $3.85, show negative momentum, while the 144 SMA at $3.79 indicates a slight bullish trend over a longer period.

In terms of momentum indicators, the 1-hour RSI at 41 suggests that INJ is approaching oversold conditions, which may present a buying opportunity in the short term. Conversely, the 7-day RSI at 51 indicates a neutral market stance, with the price having gained approximately 11.44% over the past week, reflecting overall positive sentiment.

Looking at longer-term performance, INJ has appreciated by 12.69% over the past two weeks and 27.45% over the last month, indicating a robust bullish trend. However, the significant gap from its all-time high of $52.62 poses questions about the sustainability of the current price level and the potential for future gains.

In conclusion, while the short-term indicators are mixed, the recent price appreciation and the relatively low RSI readings suggest that INJ may be poised for a rebound. Therefore, the recommendation is to **Buy** given the potential for upside in the near term and the established bullish trend over the past month.